title: Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
authors.affiliation: Tumor Biology Center, Albert-Ludwigs-University Freiburg, Germany. mross@tumorbio.uni-freiburg.de
authors.forename: K
authors.initials: K
authors.lastname: Mross
authors.forename: S
authors.initials: S
authors.lastname: Steinbild
authors.forename: F
authors.initials: F
authors.lastname: Baas
authors.forename: M
authors.initials: M
authors.lastname: Reil
authors.forename: P
authors.initials: P
authors.lastname: Buss
authors.forename: S
authors.initials: S
authors.lastname: Mersmann
authors.forename: D
authors.initials: D
authors.lastname: Voliotis
authors.forename: B
authors.initials: B
authors.lastname: Schwartz
authors.forename: E
authors.initials: E
authors.lastname: Brendel
mesh_terms: D000284:Administration, Oral; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D001557:Benzenesulfonates / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D006801:Humans; D000077146:Irinotecan; D009369:Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D019908:Proto-Oncogene Proteins c-raf / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D000077157:Sorafenib
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077146:Irinotecan; D000077157:Sorafenib; D019908:Proto-Oncogene Proteins c-raf; D002166:Camptothecin